MedTrace Logo

Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis

NCT01987167 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2017-08-22

No results posted yet for this study

Summary

The goal of the study is to determine the earliest structural changes in the optic nerve during the acute event and during the twelve months of recovery following Acthar treatment.

Conditions

Interventions

DRUG

ACTHAR

Injectable Gel

Sponsors & Collaborators

  • Mallinckrodt

    collaborator INDUSTRY

  • Neuro-Ophthalmologic Associates, PC

    lead OTHER

Principal Investigators

  • Robert C Sergott, M.D.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01987167 on ClinicalTrials.gov